{
    "ticker": "PTVE",
    "name": "Pivotal Therapeutics Inc.",
    "description": "Pivotal Therapeutics Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative therapeutic solutions for cardiovascular diseases. Founded in 2008 and headquartered in Toronto, Canada, Pivotal Therapeutics focuses on addressing the unmet medical needs of patients with cardiovascular conditions through its proprietary products that enhance patient care and improve health outcomes. The company\u2019s lead product, Vascazen, is an omega-3 fatty acid prescription product designed to improve the management of cardiovascular disease and reduce the risk of heart-related complications. Pivotal\u2019s commitment to research and development is pivotal to its strategy, enabling the advancement of its clinical pipeline and the potential for new therapeutic options. The company is actively engaged in clinical trials and collaborations aimed at expanding its product offerings and enhancing patient access to effective treatments. With a strong emphasis on scientific validation and clinical efficacy, Pivotal Therapeutics strives to make a meaningful impact on the health and well-being of patients suffering from cardiovascular diseases. The company aims to leverage its expertise in biopharmaceuticals to address the challenges in cardiovascular health, ultimately contributing to improved patient outcomes and quality of life.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Toronto, Ontario, Canada",
    "founded": "2008",
    "website": "https://www.pivotaltherapeutics.com",
    "ceo": "Dr. William W. McGowan",
    "social_media": {
        "twitter": "https://twitter.com/PivotalThera",
        "linkedin": "https://www.linkedin.com/company/pivotal-therapeutics/"
    },
    "investor_relations": "https://www.pivotaltherapeutics.com/investor-relations/",
    "key_executives": [
        {
            "name": "Dr. William W. McGowan",
            "position": "CEO"
        },
        {
            "name": "Dale D. Demby",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Cardiovascular Therapeutics",
            "products": [
                "Vascazen"
            ]
        }
    ],
    "seo": {
        "meta_title": "Pivotal Therapeutics Inc. | Innovative Cardiovascular Solutions",
        "meta_description": "Learn about Pivotal Therapeutics Inc., a biopharmaceutical company focused on developing innovative treatments for cardiovascular diseases. Discover our products and commitment to improving patient outcomes.",
        "keywords": [
            "Pivotal Therapeutics",
            "Cardiovascular Disease",
            "Biopharmaceuticals",
            "Vascazen",
            "Heart Health"
        ]
    },
    "faq": [
        {
            "question": "What does Pivotal Therapeutics specialize in?",
            "answer": "Pivotal Therapeutics specializes in developing innovative therapeutic solutions for cardiovascular diseases."
        },
        {
            "question": "What is Vascazen?",
            "answer": "Vascazen is an omega-3 fatty acid prescription product designed to improve the management of cardiovascular disease."
        },
        {
            "question": "Where is Pivotal Therapeutics located?",
            "answer": "Pivotal Therapeutics is headquartered in Toronto, Ontario, Canada."
        },
        {
            "question": "When was Pivotal Therapeutics founded?",
            "answer": "Pivotal Therapeutics was founded in 2008."
        }
    ],
    "competitors": [
        "AMRN",
        "PRTA",
        "AVLR"
    ],
    "related_stocks": [
        "JNJ",
        "PFE",
        "MRK"
    ]
}